CureVac Shares Down 12%
15 Octobre 2021 - 9:22PM
Dow Jones News
By Josh Beckerman
CureVac NV shares were recently down 12%, to $39.99, three days
after it said it would end development of its first-generation
Covid-19 vaccine candidate.
According to a Reuters report citing German newspaper Rheinische
Post, Bayer AG and CureVac terminated a vaccine production
agreement.
On Thursday, CureVac shareholder Dievini Hopp Biotech Holding
GmbH filed an amended Form 13-D with the U.S. Securities and
Exchange Commission. The amendment reflects an internal
reorganization related to share ownership and the transfer of some
shares to CureVac in connection with an investment and
shareholders' agreement.
The company said in June that the first-generation CVnCoV
vaccine was 48% effective in providing protection against Covid-19
of any severity, a lower figure than the vaccines approved in the
U.S. In August, CureVac reported favorable preclinical data for a
second-generation vaccine candidate.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 15, 2021 15:07 ET (19:07 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
CureVac NV (NASDAQ:CVAC)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
CureVac NV (NASDAQ:CVAC)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
